Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Opening Session Panel Discussion

Advertisement

Advertisement




Apr
01
Today In Oncology
Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer (1)
Early Results From a Trial of Active Surveillance for Low-Risk DCIS Are Reassuring Say Researchers
AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC
Machine-Learning Model for HCC Risk Prediction May Outperform Current Methods
Nivolumab With or Without Ipilimumab in Platinum-Refractory Advanced Neuroendocrine Carcinoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo